An international clinical trial aimed at finding treatments for Alzheimer’s disease has expanded to include investigational drugs targeting a harmful form of the brain protein tau. Originally focused on amyloid-based therapies, the trial launched with funding from the National Institute on Aging (NIA) of the National Institutes of Health (NIH) in 2013. Source: HEC Media
Washington University in St. Louis Leads International Alzheimer’s Clinical Trial to Test Tau Drugs
